Safety and efficacy of long-term open-label dosing of subcutaneous (SC) romiplostim in children with immune thrombocytopenia (ITP)

Authors
Category Primary study
ConferencePediatric Blood and Cancer
Year 2017
This article has no abstract
Epistemonikos ID: 74fc4bbca2e12297f387257e5fde619e61eb2ae6
First added on: Apr 29, 2026